The reimbursement approval in Japan is a critical regulatory milestone that allows Inari Medical to expand its market presence in a new region. The partnership with Medikit Co., Ltd. further strengthens its distribution network, likely leading to increased sales and revenue growth. This positive development is expected to have a favorable impact on Inari Medical's stock price in the short term.